Ethics statement
VIRUS
Ethical approval was obtained from the institutional review boards of JUH (2020/15074) and IH (378/2021/1). A verbal consent was obtained from each participant before participation. The IRB committee approved the verbal consent procedure to avoid spread of COVID-19 virus from sharing papers and pens needed during the written consent procedure. The patients’ names, their phone numbers and the date of data collection were recorded on the data collection forms. All the data was appropriately coded and analyzed anonymously. Only eligible patients who approved to take part in the research and gave an informed consent were enrolled in the study.The patients, initially recruited by a clinical pharmacist in the clinic’s waiting room were asked to be interviewed in a separate place to assure privacy. To avoid spread of Corona virus, the clinical pharmacist was wearing a mask, gloves and a face shield during the whole interview. The trial was registered in the international trial register retrospectively [ClinicalTrials.gov: Identifier NCT05664347; 23rd December 2022]. The delay in the trial registration was due to investigators being unfamiliar to the administrative procedure of trials registration especially in the initial lack of a central institutional PRS administrator. The authors confirm that all ongoing and related trials for this intervention are registered. 